Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Theodore F, Logan"'
Autor:
Michael B, Atkins, Sandra J, Lee, Bartosz, Chmielowski, Ahmad A, Tarhini, Gary I, Cohen, Thach-Giao, Truong, Helen H, Moon, Diwakar, Davar, Mark, O'Rourke, Joseph J, Stephenson, Brendan D, Curti, Walter J, Urba, Joanna M, Brell, Pauline, Funchain, Kari L, Kendra, Alexandra P, Ikeguchi, Anthony, Jaslowski, Charles L, Bane, Mark A, Taylor, Madhuri, Bajaj, Robert M, Conry, Robert J, Ellis, Theodore F, Logan, Noel, Laudi, Jeffrey A, Sosman, David G, Crockett, Andrew L, Pecora, Ian J, Okazaki, Sowjanya, Reganti, Sunandana, Chandra, Samantha, Guild, Helen X, Chen, Howard Z, Streicher, Jedd D, Wolchok, Antoni, Ribas, John M, Kirkwood
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 41(2)
Combination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4-blockade and dual BRAF/MEK inhibition have each shown significant clinical benefit in patients withIn a phase III trial, patients with treatment-naiveA total of 265 patients we
Autor:
Shilpa Gupta, Monika Joshi, James K. Schwarz, Joshua M. Lang, Arkadiusz Z. Dudek, Ajjai Alva, Yousef Zakharia, Li C Liu, Anas Al-Janadi, Eric A. Singer, Theodore F. Logan
Publikováno v:
Journal of Clinical Oncology
PURPOSE We hypothesized that bevacizumab will potentiate activity of pembrolizumab. We conducted a phase Ib/II, single-arm, multisite clinical trial of the combination in metastatic renal cell carcinoma (RCC). PATIENTS AND METHODS Patients with metas
Autor:
Bruce G. Redman, Elizabeth R. Plimack, Ulka N. Vaishampayan, Theodore F. Logan, Kim Margolin, David F. McDermott, Timothy M. Kuzel, Michael R. Harrison, Robert J. Motzer, Hans J. Hammers, Ian M. Waxman, Brian I. Rini, Alexandre Lambert, Saby George, Harry A. Drabkin
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(13)
Purpose Nivolumab is a fully human immunoglobulin G4 programmed death–1 immune checkpoint inhibitor antibody that restores T-cell immune activity. This phase II trial assessed the antitumor activity, dose-response relationship, and safety of nivolu
Autor:
Ramaprasad Srinivasan, Laurie Sherman, Paul S. Meltzer, Naomi B. Haas, David F. McDermott, Andrea L. Harzstark, Laurel M. Adams, Lone Ottesen, Jonathan E. Rosenberg, Ronald M. Bukowski, Ulka N. Vaishampayan, Mark N. Stein, Peter D. Eisenberg, Theodore F. Logan, Donald P. Bottaro, Robert S. Ross, Sandy Srinivas, W. Marston Linehan, Maria J. Merino, Keith T. Flaherty, Brian I. Rini, Toni K. Choueiri, Kevin H. Laubscher
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(2)
Purpose Foretinib is an oral multikinase inhibitor targeting MET, VEGF, RON, AXL, and TIE-2 receptors. Activating mutations or amplifications in MET have been described in patients with papillary renal cell carcinoma (PRCC). We aimed to evaluate the
Autor:
Stefania Scala, Vincenzo De Rosa, Mike A. Clark, Giuseppe Castello, Maria Teresa Melucci, Theodore F. Logan, Francesco Izzo, C. Mark Ensor, Antonio Daponte, Paolo A. Ascierto, Frederick W. Holtsberg, John S. Bomalaski, Niramol Savaraj, Alessandro Ottaiano, Archie W. Prestayko, Lynn G. Feun, Gerardo Beneduce, Ester Simeone
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23(30)
Purpose Individuals with metastatic melanoma have a poor prognosis. Many human melanomas are auxotrophic for arginine, and arginine is not an essential amino acid in humans. We hypothesized that this auxotrophy may be therapeutically exploited. A nov
Autor:
Kim Margolin, L. Flaherty, Joseph I. Clark, Walter J. Urba, David F. McDermott, Richard H. White, Christopher P.G. Tretter, Jeffrey A. Sosman, Michael S. Gordon, Steven Creech, Geoffrey R. Weiss, Janice P. Dutcher, Michael B. Atkins, John W. Smith, Robert A. Figlin, Bruce G. Redman, Theodore F. Logan
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 21(16)
Purpose: This prospective, randomized, controlled phase III trial assessed high-dose bolus interleukin-2 (IL-2) postoperatively in patients with high-risk renal cell carcinoma (RCC). Patients and Methods: Eligibility requirements were resected locall